AstraZeneca Q3 revenue rises 7% to $16.2bn as core earnings increase 19%
AstraZeneca reported Q3 2026 revenue of $16.2bn, up 7%, and core EPS up 19%, driven by growth in Oncology, R&I, and Rare Disease. The company announced 47 approvals, including four new medicines, and reconfirmed FY 2026 guidance. AstraZeneca also completed a $2bn investment in Summit Therapeutics and opened a new R&D center in Cambridge, Massachusetts.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise expectations for continued growth, especially in oncology, while the Summit investment signals strategic expansion.
Market read
AstraZeneca's earnings and guidance are material for pharma equities and may influence sector sentiment.
What to watch
Potential headwinds from Farxiga and Brilinta loss of exclusivity could temper long‑term growth.
Background
AstraZeneca released its Q3 2026 results, showing revenue growth and reaffirming FY guidance, while announcing a $2 bn equity investment in Summit Therapeutics and new collaborations.
Ticker impact
AstraZeneca reported Q3 2026 revenue up 7% and raised FY guidance, a fresh earnings disclosure.
likely modest upside as market prices in higher revenue and EPS guidance
The company beat prior expectations and reaffirmed growth guidance, which typically supports a price rise.
Market effects
Strengthens the pharma/biotech sector outlook with robust oncology growth.
Supports European and US pharma stocks after a major UK‑listed earnings beat.
Adds confidence to global healthcare investors tracking big‑cap drug makers.
Counterpoint
If the market has already priced in the guidance, the stock may face limited upside.
Key entities
- companyAstraZeneca
UK‑based pharmaceutical giant reporting Q3 results.
- companySummit Therapeutics
Recipient of a $2 bn equity investment and collaboration with AstraZeneca.
